Last reviewed · How we verify

oral mini pulse

Cairo University · FDA-approved active Small molecule Quality 19/100

The oral mini pulse is a therapeutic regimen developed by Cairo University. It is not an FDA-approved drug but rather a treatment protocol that involves the administration of low doses of corticosteroids over a short period. This approach aims to reduce inflammation and immune system activity, often used in autoimmune and inflammatory conditions. The regimen is tailored to minimize side effects while maintaining efficacy. Due to its non-FDA approved status, detailed safety and efficacy data are limited, and it is primarily used in academic and research settings.

At a glance

Generic nameoral mini pulse
SponsorCairo University
Drug classCorticosteroids
TargetGlucocorticoid receptors
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved

Approved indications

No approved indications tracked.

Pipeline indications

Common side effects

No common side effects on file.

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: